RESHORING CASE

Novo Nordisk

Company details
Code: 
Novo
Company name: 
Novo Nordisk
Company country: 
Denmark
Number of employees: 
41571
Sector: 
C - Manufacturing
Sector detail: 
C21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
Sub-sectors: 
C21.2.0 - Manufacture of pharmaceutical preparations
Reshoring details
Reshoring announcement date: 
22/12/2016
Starting implementation date: 
December, 2016
End of Implementation : 
January, 2017
Reshored to: 
Denmark
Location of affected unit(s): 
Copenhagen
Location code: 
DK01
Reshored business function: 
Administration
Partial or Total reshoring: 
Total
Reshoring governance mode: 
In house (in own facilities)
Estimated job gains: 
55
Reasons for reshoring: 
Firm's global reorganization
Case narrative: 

Novo Nordisk is a Danish pharmaceutical company. The firm has decided to move its European headquarters from Zürich (Switzerland) to the homeland, Copenhagen (Denmark). Through the relocation 55 positions are created in Denmark. Among these, 20 employees will be relocated to Switzerland, having agreed to move to Denmark. This means that the firm hired 35 new employees. The new headquarters have been opened on 2 January 2017.

Sources: 

Berlingske, 22/12/2016

Offshoring details
Offshoring location: 
Switzerland